As healthcare systems struggle to extract actionable signals from the vast volumes of unstructured clinical text—patient-reported symptoms, nursing notes, discharge summaries—a convergence of natural language processing and machine learning is beginning to reshape chronic disease management. The implications for long-term health outcomes, particularly in conditions where continuous monitoring is critical, deserve careful scrutiny.
This PRISMA-compliant systematic review and meta-analysis, registered on PROSPERO and drawing from four major databases, synthesized six studies encompassing 28,323 participants published between 2014 and 2024. Across three chronic disease domains, natural language intelligence technology (NLIT) demonstrated measurable clinical benefit. In COPD management, an artificial neural network-powered smartphone application called Re-Admit processed patient symptom reports alongside electronic health record data, achieving a 27.9% reduction in 30-day hospital readmissions and 88.46% accuracy in predicting acute exacerbations. In diabetes care, NLIT-assisted interventions improved self-management behaviors (p < 0.05) and increased diabetic retinopathy referral compliance by 19.34% (p < 0.01). Stroke rehabilitation outcomes also showed gains, with statistically significant improvements in motor function via the Wolf Motor Function Test (p = 0.02) and shoulder range of motion (p ≤ 0.01).
The breadth of conditions addressed is notable, yet the meta-analysis rests on a thin evidentiary base—only six studies—which substantially limits the strength of any pooled effect estimates. Heterogeneity in study design, patient populations, and NLIT implementations makes cross-condition comparisons inherently speculative. The Newcastle-Ottawa and QUADAS-C risk-of-bias tools were appropriately applied, though cohort studies remain observational by nature, precluding causal claims. The decade-long search window also means some included tools reflect earlier, less capable language models than today's large language model architectures. For health-conscious adults managing chronic conditions, this review signals that AI-powered symptom monitoring and decision-support tools are moving beyond proof-of-concept toward demonstrable clinical utility—but robust randomized trials are urgently needed before these tools can be recommended at scale.